# ClearSign Technologies Corp: financial statements, quarterly

CLIR · Nasdaq · CIK 1434524 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/clir.md) · [Financials](/companies/clir/financials.md) · [Filings](/companies/clir/filings.md) · [Insiders](/companies/clir/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/clir/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [85.0](/filings/0001558370-25-004155.md) | [1,274](/filings/0001558370-25-004155.md) | [1,102](/filings/0001104659-26-037699.md) | [45.0](/filings/0001104659-26-037699.md) | [1,859](/filings/0001104659-26-037699.md) | [590](/filings/0001104659-26-037699.md) | [401](/filings/0001104659-26-061940.md) | [133](/filings/0001104659-26-096539.md) | [1,029](/filings/0001104659-26-037699.md) | [3,671](/filings/0001104659-26-037699.md) | [191](/filings/0001104659-26-061940.md) | [560](/filings/0001104659-26-096539.md) |
| Cost of revenue | $k | [61.0](/filings/0001558370-24-015739.md) | [716 d](/filings/0001558370-25-004155.md) | [665](/filings/0001558370-25-007875.md) | [3.0](/filings/0001558370-25-011555.md) | [1,308](/filings/0001104659-25-112472.md) | [502 d](/filings/0001104659-26-037699.md) | [205](/filings/0001104659-26-061940.md) | [78.0](/filings/0001104659-26-096539.md) | [661](/filings/0001104659-25-112472.md) | [2,866 d](/filings/0001104659-26-037699.md) | [584](/filings/0001104659-26-061940.md) | [332](/filings/0001104659-26-096539.md) |
| Gross profit | $k | [24.0](/filings/0001558370-25-004155.md) | [558](/filings/0001558370-25-004155.md) | [437](/filings/0001104659-26-037699.md) | [42.0](/filings/0001104659-26-037699.md) | [551](/filings/0001104659-26-037699.md) | [88.0](/filings/0001104659-26-037699.md) | [196](/filings/0001104659-26-061940.md) | [55.0](/filings/0001104659-26-096539.md) | [368](/filings/0001104659-26-037699.md) | [805](/filings/0001104659-26-037699.md) | [(393)](/filings/0001104659-26-061940.md) | [228](/filings/0001104659-26-096539.md) |
| Research and development | $k | [93.0](/filings/0001558370-24-015739.md) | [299 d](/filings/0001558370-25-004155.md) | [281](/filings/0001558370-25-007875.md) | [402](/filings/0001558370-25-011555.md) | [329](/filings/0001104659-25-112472.md) | [459 d](/filings/0001104659-26-037699.md) | [447](/filings/0001104659-26-061940.md) | [247](/filings/0001104659-26-096539.md) | [310](/filings/0001104659-25-112472.md) | [418 d](/filings/0001104659-26-037699.md) | [249](/filings/0001104659-26-061940.md) | [448](/filings/0001104659-26-096539.md) |
| Selling, general and administrative | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $k | [(1,497)](/filings/0001558370-24-015739.md) | [(1,151) d](/filings/0001558370-25-004155.md) | [(1,252)](/filings/0001558370-25-007875.md) | [(2,137)](/filings/0001558370-25-011555.md) | [(1,433)](/filings/0001104659-25-112472.md) | [(1,666) d](/filings/0001104659-26-037699.md) | [(2,257)](/filings/0001104659-26-061940.md) | [(1,838)](/filings/0001104659-26-096539.md) | [(1,750)](/filings/0001104659-25-112472.md) | [(826) d](/filings/0001104659-26-037699.md) | [(2,279)](/filings/0001104659-26-061940.md) | [(1,498)](/filings/0001104659-26-096539.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(1,332)](/filings/0001558370-25-004155.md) | [(955)](/filings/0001558370-25-004155.md) | [(1,108)](/filings/0001104659-26-037699.md) | [(1,872)](/filings/0001104659-26-037699.md) | [(1,155)](/filings/0001104659-26-037699.md) | [(1,164)](/filings/0001104659-26-037699.md) | [(2,076)](/filings/0001104659-26-061940.md) | [(1,680)](/filings/0001104659-26-096539.md) | [(1,429)](/filings/0001104659-26-037699.md) | [(311)](/filings/0001104659-26-037699.md) | [(2,190)](/filings/0001104659-26-061940.md) | [(1,307)](/filings/0001104659-26-096539.md) |
| Diluted EPS | $ per share | [(0.03)](/filings/0001558370-25-004155.md) | [(0.02)](/filings/0001558370-25-004155.md) | [(0.30)](/filings/0001104659-26-037699.md) | [(0.40)](/filings/0001104659-26-037699.md) | [(0.20)](/filings/0001104659-26-037699.md) | [(0.25)](/filings/0001104659-26-037699.md) | [(0.38)](/filings/0001104659-26-061940.md) | [(0.30)](/filings/0001104659-26-096539.md) | [(0.26)](/filings/0001104659-26-037699.md) | [(0.06)](/filings/0001104659-26-037699.md) | [(0.39)](/filings/0001104659-26-061940.md) | [(0.22)](/filings/0001104659-26-096539.md) |
| Basic EPS | $ per share | [(0.03)](/filings/0001558370-25-004155.md) | [(0.02)](/filings/0001558370-25-004155.md) | [(0.30)](/filings/0001104659-26-037699.md) | [(0.40)](/filings/0001104659-26-037699.md) | [(0.20)](/filings/0001104659-26-037699.md) | [(0.25)](/filings/0001104659-26-037699.md) | [(0.38)](/filings/0001104659-26-061940.md) | [(0.30)](/filings/0001104659-26-096539.md) | [(0.26)](/filings/0001104659-26-037699.md) | [(0.06)](/filings/0001104659-26-037699.md) | [(0.39)](/filings/0001104659-26-061940.md) | [(0.22)](/filings/0001104659-26-096539.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [7.2](/filings/0001558370-23-019018.md) | [5.7](/filings/0001558370-25-004155.md) | [4.6](/filings/0001558370-24-008292.md) | [16.0](/filings/0001558370-24-012226.md) | [14.5](/filings/0001558370-24-015739.md) | [14.0](/filings/0001104659-26-037699.md) | [12.9](/filings/0001558370-25-007875.md) | [12.3](/filings/0001558370-25-011555.md) | [10.5](/filings/0001104659-25-112472.md) | [9.2](/filings/0001104659-26-096539.md) | [7.7](/filings/0001104659-26-061940.md) | [9.9](/filings/0001104659-26-096539.md) |
| Current assets | $m | [7.8](/filings/0001558370-23-019018.md) | [6.5](/filings/0001558370-25-004155.md) | [5.5](/filings/0001558370-24-008292.md) | [16.7](/filings/0001558370-24-012226.md) | [16.0](/filings/0001558370-24-015739.md) | [15.2](/filings/0001104659-26-037699.md) | [13.5](/filings/0001558370-25-007875.md) | [13.2](/filings/0001558370-25-011555.md) | [11.7](/filings/0001104659-25-112472.md) | [11.2](/filings/0001104659-26-096539.md) | [8.8](/filings/0001104659-26-061940.md) | [11.2](/filings/0001104659-26-096539.md) |
| Total assets | $m | [9.0](/filings/0001558370-23-019018.md) | [7.6](/filings/0001558370-25-004155.md) | [6.6](/filings/0001558370-24-008292.md) | [17.8](/filings/0001558370-24-012226.md) | [17.1](/filings/0001558370-24-015739.md) | [16.3](/filings/0001104659-26-037699.md) | [14.5](/filings/0001558370-25-007875.md) | [14.2](/filings/0001558370-25-011555.md) | [12.7](/filings/0001104659-25-112472.md) | [12.2](/filings/0001104659-26-096539.md) | [9.8](/filings/0001104659-26-061940.md) | [12.2](/filings/0001104659-26-096539.md) |
| Current liabilities | $m | [2.9](/filings/0001558370-23-019018.md) | [2.3](/filings/0001558370-25-004155.md) | [2.0](/filings/0001558370-24-008292.md) | [1.8](/filings/0001558370-24-012226.md) | [2.1](/filings/0001558370-24-015739.md) | [2.4](/filings/0001104659-26-037699.md) | [2.4](/filings/0001558370-25-007875.md) | [3.7](/filings/0001558370-25-011555.md) | [3.6](/filings/0001104659-25-112472.md) | [2.6](/filings/0001104659-26-096539.md) | [2.2](/filings/0001104659-26-061940.md) | [2.3](/filings/0001104659-26-096539.md) |
| Total liabilities | $m | [3.1](/filings/0001558370-23-019018.md) | [2.4](/filings/0001558370-25-004155.md) | [2.2](/filings/0001558370-24-008292.md) | [1.9](/filings/0001558370-24-012226.md) | [2.3](/filings/0001558370-24-015739.md) | [2.5](/filings/0001104659-26-037699.md) | [2.5](/filings/0001558370-25-007875.md) | [3.8](/filings/0001558370-25-011555.md) | [3.7](/filings/0001104659-25-112472.md) | [2.7](/filings/0001104659-26-096539.md) | [2.2](/filings/0001104659-26-061940.md) | [2.4](/filings/0001104659-26-096539.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [5.9](/filings/0001558370-24-015739.md) | [5.2](/filings/0001104659-26-037699.md) | [4.5](/filings/0001104659-25-112472.md) | [15.9](/filings/0001104659-25-112472.md) | [14.8](/filings/0001104659-25-112472.md) | [13.8](/filings/0001104659-26-096539.md) | [12.0](/filings/0001104659-26-096539.md) | [10.4](/filings/0001104659-26-096539.md) | [9.1](/filings/0001104659-25-112472.md) | [9.5](/filings/0001104659-26-096539.md) | [7.6](/filings/0001104659-26-096539.md) | [9.8](/filings/0001104659-26-096539.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,275) d](/filings/0001558370-24-015739.md) | [(1,450) d](/filings/0001558370-25-004155.md) | [(1,001)](/filings/0001558370-25-007875.md) | [(1,524) d](/filings/0001558370-25-011555.md) | [(1,433) d](/filings/0001104659-25-112472.md) | [(415) d](/filings/0001104659-26-037699.md) | [(1,111)](/filings/0001104659-26-061940.md) | [(511) d](/filings/0001104659-26-096539.md) | [(1,831) d](/filings/0001104659-25-112472.md) | [(1,283) d](/filings/0001104659-26-037699.md) | [(1,348)](/filings/0001104659-26-061940.md) | [(1,236) d](/filings/0001104659-26-096539.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001104659-25-112472.md) | [21.0 d](/filings/0001104659-26-037699.md) | [4.0](/filings/0001104659-26-061940.md) | [0.0 d](/filings/0001104659-26-096539.md) | [0.0 d](/filings/0001104659-25-112472.md) | [0.0 d](/filings/0001104659-26-037699.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [31.8](/filings/0001558370-23-009840.md) | [33.5](/filings/0001558370-23-014714.md) | [37.9](/filings/0001558370-23-019018.md) | [38.3](/filings/0001558370-24-008292.md) | [38.5](/filings/0001558370-24-012226.md) | [38.6](/filings/0001558370-23-019018.md) | [38.8](/filings/0001558370-25-007875.md) | [47.3](/filings/0001558370-25-011555.md) | [5.5](/filings/0001104659-26-061940.md) | [5.5](/filings/0001104659-26-096539.md) | [5.6](/filings/0001104659-26-061940.md) | [5.9](/filings/0001104659-26-096539.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 6,807,455 at 2026-08-08, from the cover of the [10-Q filed 2026-08-14](/filings/0001104659-26-096539.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.